Evidence map›Paper›PMID 39172142›Full record

ArticleCellular and molecular life sciences : CMLS2024

Comparative profiling of whole-cell and exosome samples reveals protein signatures that stratify breast cancer subtypes.

Zoraida Andreu, Marta R Hidalgo, Esther Masiá, Sergio Romera-Giner, Pablo Malmierca-Merlo, José A López-Guerrero, Francisco García-García, María J Vicent

Abstract readComparative Study
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zoraida Andreu *Polymer Therapeutics Laboratory and Screening Platform, Príncipe Felipe Research Center (CIPF), Av. Eduardo Primo Yúfera 3, Valencia, 46012, Spain. zandreu@fivo.org.
Marta R Hidalgo *IVO-CIPF Joint Cancer Research Unit, Príncipe Felipe Research Center (CIPF), Av. Eduardo Primo Yúfera 3, Valencia, 46012, Spain.
Esther MasiáPolymer Therapeutics Laboratory and Screening Platform, Príncipe Felipe Research Center (CIPF), Av. Eduardo Primo Yúfera 3, Valencia, 46012, Spain.
Sergio Romera-GinerComputational Biomedicine Laboratory, Príncipe Felipe Research Center (CIPF), Av. Eduardo Primo Yúfera 3, Valencia, 46012, Spain.
Pablo Malmierca-MerloComputational Biomedicine Laboratory, Príncipe Felipe Research Center (CIPF), Av. Eduardo Primo Yúfera 3, Valencia, 46012, Spain.
José A López-GuerreroIVO-CIPF Joint Cancer Research Unit, Príncipe Felipe Research Center (CIPF), Av. Eduardo Primo Yúfera 3, Valencia, 46012, Spain.
Francisco García-GarcíaIVO-CIPF Joint Cancer Research Unit, Príncipe Felipe Research Center (CIPF), Av. Eduardo Primo Yúfera 3, Valencia, 46012, Spain. fgarcia@cipf.es.
María J VicentPolymer Therapeutics Laboratory and Screening Platform, Príncipe Felipe Research Center (CIPF), Av. Eduardo Primo Yúfera 3, Valencia, 46012, Spain. mjvicent@cipf.es.ORCID http://orcid.org/0000-0001-7771-3373

Funding

H2020 European Research Council ERC-CoG-2014-648831 "MyNano"Horizon 2020 Framework Programme the H2020 EU-OpenScreen-Drive project (grant agreement No. 823893)Instituto de Salud Carlos III CIBERONC project n. CB22/12/00048Instituto de Salud Carlos III project IMPaCT-Data, IMP/00019Ministerio de Ciencia e Innovación PID2019-108806RB-I00 and Excellence Network Tentacles-RED2018-102411-TMinisterio de Ciencia e Innovación PID2021-124430OA-I00 funded by MCIN/AEI/10.13039/501100011033/ FEDER, UE ("A way to make Europe")
6 · The paper itself

Abstract

Identifying novel breast cancer biomarkers will improve patient stratification, enhance therapeutic outcomes, and help develop non-invasive diagnostics. We compared the proteomic profiles of whole-cell and exosomal samples of representative breast cancer cell subtypes to evaluate the potential of extracellular vesicles as non-invasive disease biomarkers in liquid biopsies. Overall, differentially-expressed proteins in whole-cell and exosome samples (which included markers for invasion, metastasis, angiogenesis, and drug resistance) effectively discriminated subtypes; furthermore, our results confirmed that the proteomic profile of exosomes reflects breast cancer cell-of-origin, which underscores their potential as disease biomarkers. Our study will contribute to identifying biomarkers that support breast cancer patient stratification and developing novel therapeutic strategies. We include an open, interactive web tool to explore the data as a molecular resource that can explain the role of these protein signatures in breast cancer classification.

Indexed as

Biomarkers, TumorBreast NeoplasmsExosomesProteomicsCell Line, TumorFemaleHumansProteomeBiomarkers, TumorProteomeBreast cancer-derived exosomesDisease biomarkersGO analysisNetwork analysisProteomic signatures

Identifiers

PMID39172142
PMCPMC11342910

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.